Hims & Hers will cut 68 employees, or about 4% of its workforce, as it adjusts to the U.S. ban on manufacturing mass copies of Wegovy, Amina Niasse of Reuters reports. These changes are focused on sharpening how we execute, without affecting our priorities or the specialties we’re committed to,” a company spokesperson said regarding the layoffs, according to Reuters.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- LifeMD price target raised to $15 from $12 at BTIG
- Mixed options sentiment in Hims and Hers Health with shares up 2.0%
- Why Hims & Hers Health Stock (HIMS) Is Too Hot to Handle
- ‘Time to Choose Sides on HIMS Stock’ as Analysts Assign Mixed Ratings
- Hims & Hers introduces 6-month Wegovy new customer offer